Cameron DURRANT
8Patents
2h-index
3Co-inventors
33Inventor score
Filing activity: Oct 2, 2018 → Nov 9, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10813907B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | Chemistry; Metallurgy | 3 | Active |
| US10899831B2 | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity | Chemistry; Metallurgy | 2 | Active |
| US10927168B2 | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab | Chemistry; Metallurgy | 2 | Active |
| US10870703B2 | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist | Chemistry; Metallurgy | 2 | Active |
| US11130805B2 | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist | Chemistry; Metallurgy | 0 | Active |
| US11690821B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | Chemistry; Metallurgy | 0 | Active |
| US12139544B2 | EphA3 directed CAR-T cells for treatment of tumors | Chemistry; Metallurgy | 0 | Active |
| US11673962B2 | Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.